Shipo Wu , Gongxun Zhong , Jun Zhang , Lei Shuai , Zhe Zhang , Zhiyuan Wen , Busen Wang , Zhenghao Zhao , Xiaohong Song , Yi Chen , Renqiang Liu , Ling Fu, Jinlong Zhang , Qiang Guo , Chong Wang , Yilong Yang , Ting Fang, Peng Lv , Jinliang Wang , Junjie Xu , Jianmin Li , Changming Yu , Lihua Hou , Zhigao Bu , Wei Chen
Nat Commun. 2020 Aug 14;11(1):4081.doi: 10.1038/s41467-020-17972-1.
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.